PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
London S.E.
18:35:05 21/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 117.60 GBX | +0.68% |
|
-1.01% | -5.92% |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| 07-13 | PureTech Health: Celea Therapeutics Kicks Off Late-stage Trial for Idiopathic Pulmonary Fibrosis Drug | MT |
| Market Cap | 388M 332M 311M 285M 534M 37.11B 541M 3.67B 1.43B 18.64B 1.46B 1.42B 61.66B | P/E 2026 * |
-3.49x | P/E 2027 * | -4.17x |
|---|---|---|---|---|---|
| Enterprise Value | 119M 102M 95.32M 87.26M 164M 11.38B 166M 1.13B 439M 5.72B 447M 437M 18.91B | EV / Sales 2026 * |
16.8x | EV / Sales 2027 * | 10.7x |
| Free-Float |
84.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PureTech Health plc
| 1 day | +0.34% | ||
| 1 week | -1.01% | ||
| Current month | -1.18% | ||
| 1 month | -6.81% | ||
| 3 months | -10.23% | ||
| 6 months | -5.92% | ||
| Current year | -5.92% |
| 1 week | 113 |  | 121 |
| 1 month | 113 | | 126.4 |
| Current year | 107.4 | | 143.6 |
| 1 year | 104.71 | | 143.6 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 410.66 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 9/24/25 A | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 9/24/25 A | Buy | Director | 29,239 | 0.0122% | ||
| 9/24/25 A | Buy | Chairman | 65,250 | 0.0272% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.68% | -1.01% | -12.11% | -35.81% | 388M | |
| +1.09% | +5.26% | +4.44% | +26.03% | 51.22B | |
| -1.11% | +2.20% | +470.70% | +596.99% | 45.38B | |
| +1.68% | +8.08% | +19.62% | +91.50% | 41.97B | |
| +1.68% | +9.70% | +40.04% | +21.12% | 42.15B | |
| -0.93% | -4.80% | +17.39% | +46.60% | 31.95B | |
| -0.65% | +3.04% | - | - | 16.73B | |
| +1.37% | +7.55% | +37.24% | +152.94% | 17.1B | |
| +0.03% | +3.91% | +5.84% | +35.04% | 14.76B | |
| +1.35% | +5.75% | +91.63% | +47.40% | 13.91B | |
| Average | +0.46% | +2.43% | +74.98% | +109.09% | 27.56B | |
| Weighted average by Cap. | +0.50% | +3.12% | +102.96% | +148.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.1M 6.08M 5.69M 5.21M 9.78M 679M 9.91M 67.23M 26.22M 341M 26.66M 26.08M 1.13B | 13.47M 11.54M 10.79M 9.88M 18.54M 1.29B 18.79M 128M 49.73M 647M 50.57M 49.47M 2.14B |
| Net income | -124M -106M -99.47M -91.05M -171M -11.87B -173M -1.18B -458M -5.96B -466M -456M -19.73B | -96.8M -82.92M -77.59M -71.02M -133M -9.26B -135M -917M -357M -4.65B -363M -356M -15.39B |
| Net Debt | -269M -230M -216M -197M -370M -25.73B -375M -2.55B -993M -12.93B -1.01B -988M -42.75B | -244M -209M -196M -179M -336M -23.38B -341M -2.31B -902M -11.75B -918M -898M -38.85B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/08/26 | GBX 117.60 | +0.68% | 437,932 |
| 20/08/26 | GBX 116.80 | -2.01% | 242,226 |
| 19/08/26 | GBX 119.20 | +2.94% | 319,050 |
| 18/08/26 | GBX 115.80 | -1.53% | 791,892 |
| 17/08/26 | GBX 117.60 | -1.01% | 237,513 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
